問題一覧
1
Reduction of risk of Ml. stroke, and coronary revascularzation in adults with cardiovascular disease, adjunct to diet, alone or in combination with other therapies to lower LDL, in adults with primary hyperlipidemia, adjunct to other therapies to lower LDL in patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL
evolocumab (Repatha)
2
general term used for drugs e used to lower lipid levels in the blood
antihyperlipidemic agents
3
type of fat with a phosphate grous important structure to make lipoproteins, blood-clotting components, the myelin sheath, and cell membranes
proprotein convertase subtilisin/kexin type 9 (PCSK9)
4
5. Which would alert the nurse to suspect that a patient receiving HMG-CoA reductase inhibitors is developing rhabdomyelysis? a. Flatulence and abdominal bloating b. Increased bleeding and bruising Development of cataracts and blurred vision Muscle pain and weaknesss. Which would alert the nurse to suspect that a patient receiving HMG-CoA reductase inhibitors is developing rhabdomyelysis?
d. Muscle pain and weakness
5
7. Which would the nurse expect the health care provider to prescribe for a patient who has high lipid levels and cannot take fibrates or HMG-CoA reductase inhibitors?
c. PCSK9 inhibitor
6
collection of factors, including insulin resistance, abdominal obesity, low high-density lipoprotein, high triglyceride levels, hypertension, and proinflammatory and prothrombotic states, that increase the incidence.of atherosclerotic cardiovascular disease
metabolic syndrome
7
The formation of atheromas in blood vessels precedes the signs and symptoms of
b. atherosclerotic cardiovascular disease.
8
Reduction of risk of Mi, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease, adjunet to diet, alone or in compination with other therapies to lower LDL, in adults with primary hyperlipidemia, adjunct to other therapies to lower LDL in adult patients with. homozygous familial hypercholesterolemia (HoFH) to reduce LDL
alirocumab (Praluent)
9
carrier for lipids in the bloodstream, consisting of proteins, lipids, cholesterol, and other components
chylomicron
10
tightly packed fats that are thought to contribute to the development of atherosclerotic cardiovascular disease when remnants left over trom the LDL are processed in the arterial lining
low-density lipoprotein
11
1. Which of the following descriptions accurately reflects how the body uses cholesterol?
b. Formation of steroid hormones
12
increased levels of lipids in the serum, associated with increased risk of development of atherosclerotic cardiovascular disease
hyperlipidemia
13
type of fat with a phosphate grous important structure to make lipoproteins, blood-clotting components, the myelin sheath, and cell membranes
phospholipids
14
5. HMG-CoA reductase inhibitors work in the
b. process of cholesterol formation in the cell.
15
3. Hyperlipidemia is considered to be a
c. treatable ASCVD risk factor
16
6. When teaching a patient about HMG-CoA reductase inhibitors, the nurse would include that the patient
c. might develop cataracts as a result.
17
loosely packed chylomicron-containing fats, able to absorb fats and fat remnants in the periphery; thought to have a protective effect, decreasing the development of atherosclerotic cardiovascular disease
high-density lipoprotein (HDL)
18
type of lipid that is also called " neutral fat*: composed of fatty acids and a glycerol molecule; primarily used in the bedy as a source of energy
triglycerides
19
4. The bile acid sequestrants
d. prevent bile salts from being reabsorbed.
20
formation of steroid hormones
cholesterol
21
cholesterol-containing acids found in the bile that act like detergents to break up fats in the small intestine
bile acids
22
enzyme that regulates the last step in cellular cholesterol synthesis
hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase